Virtual Screening for Identification of Dual Inhibitors against CDK4/6 and Aromatase Enzyme.

ABSTRACT: CDK4/6 and aromatase are prominent targets for breast cancer drug discovery and are involved in abnormal cell proliferation and growth. Although aromatase inhibitors have proven to be effective (for example exemestane, anastrozole, letrozole), resistance to treatment eventually occurs through the activation of alternative signaling pathways, thus evading the antiproliferative effects of aromatase inhibitors. One of the evasion pathways is Cylin D-CDK4/6-Rb signaling that promotes tumor proliferation and resistance to aromatase inhibitors. There is significant evidence that the sequential inhibition of both proteins provides therapeutic benefits over the inhibition of one target. The basis of this study objective is the identification of molecules that are likely to inhibit both CDK4/6 and

SUBMITTER: Adon T 

PROVIDER: S-EPMC10058413 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature